• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-in-human administration of [Tb]Tb-SibuDAB and comparative dosimetry with standard [Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.

作者信息

Chirindel Alin, Nicolas Guillaume P, Westerbergh Frida, McDougall Lisa, Schmid David E, Geistlich Susanne, Tschan Viviane J, Busslinger Sarah D, Fokkema Angelique, Aceto Nicola, Bernhardt Peter, van der Meulen Nicholas P, Müller Cristina, Wild Damian, Schibli Roger

机构信息

Division of Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031, Switzerland.

Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

出版信息

Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1628-1630. doi: 10.1007/s00259-024-07009-w. Epub 2024 Dec 5.

DOI:10.1007/s00259-024-07009-w
PMID:39633183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11928360/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5499/11928360/e12abc5259f5/259_2024_7009_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5499/11928360/e12abc5259f5/259_2024_7009_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5499/11928360/e12abc5259f5/259_2024_7009_Figa_HTML.jpg

相似文献

1
First-in-human administration of [Tb]Tb-SibuDAB and comparative dosimetry with standard [Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study.作为PROGNOSTICS Ia期研究的一部分，[Tb]Tb-SibuDAB的首次人体给药及与标准[Lu]Lu-PSMA-I&T的比较剂量测定。
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1628-1630. doi: 10.1007/s00259-024-07009-w. Epub 2024 Dec 5.
2
Albumin-Binding and Conventional PSMA Ligands in Combination with Tb: Biodistribution, Dosimetry, and Preclinical Therapy.白蛋白结合型和传统 PSMA 配体联合 Tb：生物分布、剂量学和临床前治疗。
J Nucl Med. 2023 Oct;64(10):1625-1631. doi: 10.2967/jnumed.123.265524. Epub 2023 Jul 13.
3
Biodistribution and dosimetry of [Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.[镥]Lu-SibuDAB在转移性去势抵抗性前列腺癌患者中的生物分布与剂量测定
Eur J Nucl Med Mol Imaging. 2025 Feb 3. doi: 10.1007/s00259-025-07102-8.
4
Preclinical Investigations to Explore the Difference between the Diastereomers [Lu]Lu-SibuDAB and [Lu]Lu-RibuDAB toward Prostate Cancer Therapy.临床前研究探索[Lu]Lu-SibuDAB 和 [Lu]Lu-RibuDAB 对前列腺癌治疗的立体异构体差异。
Mol Pharm. 2022 Jul 4;19(7):2105-2114. doi: 10.1021/acs.molpharmaceut.1c00994. Epub 2022 May 11.
5
[Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [Ac]Ac-PSMA-617.用于前列腺癌靶向α治疗的[Ac]Ac-SibuDAB：临床前评估及与[Ac]Ac-PSMA-617的比较
Cancers (Basel). 2022 Nov 17;14(22):5651. doi: 10.3390/cancers14225651.
6
[Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lu]Lu-PSMA-617.镥[177Lu]比伐卢定联合替罗非班治疗急性 ST 段抬高型心肌梗死的疗效及安全性
Theranostics. 2024 Feb 24;14(5):1829-1840. doi: 10.7150/thno.92273. eCollection 2024.
7
Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.在DOTA-TATE和PSMA-617治疗中用Tb-161替代Lu-177：活性选择的潜在剂量学影响。
EJNMMI Phys. 2023 Nov 10;10(1):69. doi: 10.1186/s40658-023-00589-w.
8
Inductively Coupled Plasma Mass Spectrometry─A Valid Method for the Characterization of Metal Conjugates in View of the Development of Radiopharmaceuticals.电感耦合等离子体质谱法-放射性药物开发视角下金属结合物表征的有效方法。
Mol Pharm. 2023 Apr 3;20(4):2150-2158. doi: 10.1021/acs.molpharmaceut.2c01092. Epub 2023 Feb 24.
9
Dosimetry of [Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis.[镥 Lu]Lu-PSMA 靶向放射性药物治疗前列腺癌的剂量学：一项比较系统的综述和荟萃分析。
J Nucl Med. 2024 Aug 1;65(8):1264-1271. doi: 10.2967/jnumed.124.267452.
10
Design and Preclinical Evaluation of a Novel Prostate-Specific Membrane Antigen Radioligand Modified with a Transthyretin Binder.一种经甲状腺转运蛋白结合剂修饰的新型前列腺特异性膜抗原放射性配体的设计与临床前评估。
Cancers (Basel). 2024 Mar 23;16(7):1262. doi: 10.3390/cancers16071262.

引用本文的文献

1
Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.架起物理与实践的桥梁：评估铽-161γ相机成像中的灵敏度、隔层穿透及探测器死时间
EJNMMI Phys. 2025 Aug 28;12(1):81. doi: 10.1186/s40658-025-00792-x.
2
Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering.通过分子工程在独特的保守赖氨酸位点进行位点特异性标记来增强抗间皮素单域抗体的诊疗潜力。
EJNMMI Radiopharm Chem. 2025 Apr 28;10(1):19. doi: 10.1186/s41181-025-00340-z.
3
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

本文引用的文献

1
Albumin-Binding and Conventional PSMA Ligands in Combination with Tb: Biodistribution, Dosimetry, and Preclinical Therapy.白蛋白结合型和传统 PSMA 配体联合 Tb：生物分布、剂量学和临床前治疗。
J Nucl Med. 2023 Oct;64(10):1625-1631. doi: 10.2967/jnumed.123.265524. Epub 2023 Jul 13.
2
Dosimetric Analysis of the Short-Ranged Particle Emitter Tb for Radionuclide Therapy of Metastatic Prostate Cancer.用于转移性前列腺癌放射性核素治疗的短程粒子发射体铽的剂量学分析
Cancers (Basel). 2021 Apr 22;13(9):2011. doi: 10.3390/cancers13092011.
3
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
编辑委员会重点介绍放射化学和放射性药物的发展成果。
EJNMMI Radiopharm Chem. 2025 Mar 25;10(1):13. doi: 10.1186/s41181-025-00335-w.
4
Preclinical investigation of [Tb]Tb-DOTATATE and [Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy.用于肿瘤靶向α治疗的[铽]铽-多柔比星和[铽]铽-多柔比星-LM3的临床前研究。
Eur J Nucl Med Mol Imaging. 2025 Mar;52(4):1383-1398. doi: 10.1007/s00259-024-07035-8. Epub 2025 Jan 2.
镱-161 用于 PSMA 靶向放射性核素治疗前列腺癌。
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1919-1930. doi: 10.1007/s00259-019-04345-0. Epub 2019 May 27.